[Dormant tumors and organs resistant to metastasis after gene transfer: dream and reality of anti-angiogenic gene therapy].
Treating cancer by targeting its vasculature is a recent conceptual revolution. The use of newly discovered potent antiangiogenic factors has confirmed the anti-growth and anti-metastatic efficiency of anti-angiogenic therapy in a variety of experimental solid tumour models. Using gene transfer technique to deliver anti-angiogenic molecules in vivo is becoming a widely accepted new approach. This review summarizes the biological basis, current situation and development trends of this new therapy, as well as its promising perspectives in cancer treatment.
Li
H
H
DIFEMA, Faculté de Médecine et de Pharmacie de Rouen, 22 Avenue Gambetta, 76000 Rouen, France.
Dkhissi
F
F
Grenet
C
C
Soria
C
C
Lu
H
H
D020533:Angiogenesis Inhibitors / Q000235:genetics / Q000627:therapeutic use*; D015316:Genetic Therapy; D006801:Humans; D007113:Immunity, Innate; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors